JP2002173442A - Antifatigue composition - Google Patents

Antifatigue composition

Info

Publication number
JP2002173442A
JP2002173442A JP2000368299A JP2000368299A JP2002173442A JP 2002173442 A JP2002173442 A JP 2002173442A JP 2000368299 A JP2000368299 A JP 2000368299A JP 2000368299 A JP2000368299 A JP 2000368299A JP 2002173442 A JP2002173442 A JP 2002173442A
Authority
JP
Japan
Prior art keywords
meat
imidazole
fatigue
composition
anserine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000368299A
Other languages
Japanese (ja)
Other versions
JP4873778B2 (en
Inventor
Yoshiharu Matahira
芳春 又平
Kazuaki Kikuchi
数晃 菊地
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yaizu Suisan Kagaku Kogyo Co Ltd
Original Assignee
Yaizu Suisan Kagaku Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yaizu Suisan Kagaku Kogyo Co Ltd filed Critical Yaizu Suisan Kagaku Kogyo Co Ltd
Priority to JP2000368299A priority Critical patent/JP4873778B2/en
Priority to US09/933,438 priority patent/US6855727B2/en
Priority to TW090120843A priority patent/TWI221413B/en
Priority to DE60124658T priority patent/DE60124658T2/en
Priority to AT01307418T priority patent/ATE345798T1/en
Priority to EP01307418A priority patent/EP1210940B1/en
Priority to KR1020010053099A priority patent/KR100805163B1/en
Priority to CN01141170A priority patent/CN1356103A/en
Publication of JP2002173442A publication Critical patent/JP2002173442A/en
Application granted granted Critical
Publication of JP4873778B2 publication Critical patent/JP4873778B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide a functional food material containing extracts obtained from fish, shellfish, poultry, meat, etc. SOLUTION: An antifatigue composition having performance-enhancing and antifatigue effects is produced by using imidazole dipeptides and/or their salts as active components. The imidazole dipeptide of the antifatigue composition is preferably one or more compounds selected from anserine, carnosine and valenine. The content of the imidazole dipeptide and/or its salt is preferably 10-100 mass%.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【産業上の利用分野】本発明は、魚介類、鳥肉、畜肉等
から得られるイミダゾールジペプチド類を利用した抗疲
労組成物に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an anti-fatigue composition using imidazole dipeptides obtained from fish, shellfish, poultry meat, animal meat and the like.

【0002】[0002]

【従来の技術】激しい運動を行なうと、筋肉にあるグリ
コーゲン由来のグルコースが利用され、無酸素的な解糖
反応が進行して筋肉の収縮に必要なATPが合成され
る。そして、その代謝産物である乳酸が蓄積して筋肉内
pHの低下が起こり、筋収縮の効率が落ちてくる。この
状態は代謝性アシドーシスと言われており、その結果、
筋肉疲労に至ると考えられている。そのため、持続的な
運動による筋肉疲労を抑制するためには、代謝性アシド
ーシスを引き起こさないことが重要である。
2. Description of the Related Art When intense exercise is performed, glucose derived from glycogen in muscle is used, and an anaerobic glycolysis reaction proceeds to synthesize ATP necessary for muscle contraction. Then, lactic acid, which is a metabolite thereof, accumulates to cause a decrease in intramuscular pH, and the efficiency of muscle contraction decreases. This condition is called metabolic acidosis, and as a result,
It is thought to lead to muscle fatigue. Therefore, in order to suppress muscle fatigue due to continuous exercise, it is important not to cause metabolic acidosis.

【0003】近年、スポーツ選手の間でサプリメントと
してクレアチンの摂取が盛んに行われている。クレアチ
ンは体内でクレアチンリン酸に変換され、高エネルギー
リン酸化合物としてエネルギーを運搬する働きを有し、
またATPの合成に不可欠な成分であり、クレアチンの
摂取により筋肉のクレアチン含量が増加し、高強度の運
動のパフォーマンスが向上することが知られている(Ha
rris, R. C. et al:Clin. Sci., 83, 367-374, 199
2)。
[0003] In recent years, creatine has been actively taken as a supplement among athletes. Creatine is converted to creatine phosphate in the body and has the function of transferring energy as a high-energy phosphate compound,
It is also an essential component of ATP synthesis, and it is known that ingestion of creatine increases the creatine content of muscle and improves the performance of high-intensity exercise (Ha
rris, RC et al: Clin. Sci., 83, 367-374, 199
2).

【0004】また、エネルギー源としてのグリコーゲン
が不足すると、体脂肪がより利用されやすくなると共に
血中アミノ酸がエネルギーに変換されることから、血中
アミノ酸の濃度をできるだけ高め、エネルギー源として
利用して筋肉疲労や筋力低下を改善する試みもなされて
いる。特にエネルギーとして利用されやすいアミノ酸
は、分岐鎖アミノ酸(ロイシン、イソロイシン、バリ
ン)であり、例えば特開昭58−16577号、特開平
7−25838号及び特開2000−26290号に
は、上記分岐鎖アミノ酸を食品として利用することが提
案されている。
[0004] In addition, when glycogen as an energy source is insufficient, body fat is more easily used and blood amino acids are converted into energy. Attempts have been made to improve muscle fatigue and muscle weakness. Amino acids particularly easily used as energy are branched-chain amino acids (leucine, isoleucine, and valine). For example, JP-A-58-16577, JP-A-7-25838 and JP-A-2000-26290 disclose the branched chain amino acids. It has been proposed to use amino acids as foods.

【0005】さらに、特開平8−198748号及び特
開平9−249556号には、運動機能の向上と疲労回
復効果を目的として、スズメバチ(Vespar属)の幼虫が
分泌する唾液に含まれるアミノ酸類に準じて構成された
アミノ酸組成物を投与することにより、血中アミノ酸の
変動を抑制することが提案されている。
Further, Japanese Patent Application Laid-Open Nos. Hei 8-198748 and Hei 9-249556 disclose amino acids contained in saliva secreted by larvae of hornets (Vespar) for the purpose of improving motor function and recovering from fatigue. It has been proposed to suppress fluctuations in blood amino acids by administering an amino acid composition configured in accordance with the composition.

【0006】[0006]

【発明が解決しようとする課題】ところで、魚介類、鳥
肉、畜肉等から得られるエキス類は様々なアミノ酸類を
含んでおり、一般には調味料として広く利用されている
が、その生理活性機能についてはほとんど研究されてい
ない。
By the way, extracts obtained from fish, shellfish, poultry meat, animal meat and the like contain various amino acids and are generally widely used as seasonings. Has been little studied.

【0007】従って、本発明の目的は、魚介類、鳥肉、
畜肉等から得られるエキス類を利用した機能性食品素材
を提供することにある。
Accordingly, an object of the present invention is to provide fish, seafood, poultry,
An object of the present invention is to provide a functional food material using extracts obtained from meat or the like.

【0008】[0008]

【課題を解決するための手段】本発明者らは、カツオや
マグロの肉から調製された調味料エキスの生理活性機能
を研究する過程で、該エキス中に多量に含まれるイミダ
ゾールジペプチド類に着目し、鋭意研究した結果、イミ
ダゾールジペプチド類に運動能力の向上効果、すなわち
抗疲労効果があることを発見し、この事実に基づいて本
発明を完成するに至った。
Means for Solving the Problems In the course of studying the physiologically active function of a seasoning extract prepared from skipjack and tuna meat, the present inventors have focused on imidazole dipeptides contained in the extract in large amounts. As a result of intensive studies, they have found that imidazole dipeptides have an effect of improving exercise ability, that is, an anti-fatigue effect, and based on this fact, have completed the present invention.

【0009】本発明の抗疲労組成物は、イミダゾールジ
ペプチド類及び/又はその塩を有効成分として含有する
ことを特徴とする。
The anti-fatigue composition of the present invention is characterized by containing an imidazole dipeptide and / or a salt thereof as an active ingredient.

【0010】本発明においては、前記イミダゾールジペ
プチド類が、アンセリン、カルノシン及びバレニンから
選ばれた少なくとも1種以上であることが好ましい。ま
た、前記イミダゾールジペプチド類及び/又はその塩を
10〜100質量%含有することが好ましい。
In the present invention, the imidazole dipeptides are preferably at least one selected from anserine, carnosine and varenin. Further, it is preferable to contain the imidazole dipeptides and / or salts thereof in an amount of 10 to 100% by mass.

【0011】本発明によれば、従来、調味料として利用
されてきた魚介類、鳥肉、畜肉等から得られるエキス類
を利用した新たな抗疲労組成物を提供できる。
According to the present invention, a new anti-fatigue composition using extracts obtained from fish, shellfish, poultry, livestock meat and the like which have been conventionally used as seasonings can be provided.

【0012】[0012]

【発明の実施の形態】本発明の抗疲労組成物の有効成分
であるイミダゾールジペプチド類としては、主にアンセ
リン(β−アラニル−1−メチルヒスチジン)、カルノ
シン(β−アラニルヒスチジン)、バレニン(β−アラ
ニル−3−メチルヒスチジン)が挙げられる。本発明の
抗疲労組成物においては、アンセリン、カルノシン、バ
レニンから選ばれた少なくとも1種以上を有効成分とし
て含有することが好ましい。
BEST MODE FOR CARRYING OUT THE INVENTION The imidazole dipeptides which are the active ingredients of the anti-fatigue composition of the present invention mainly include anserine (β-alanyl-1-methylhistidine), carnosine (β-alanylhistidine), and varenin ( β-alanyl-3-methylhistidine). The anti-fatigue composition of the present invention preferably contains at least one or more selected from anserine, carnosine, and varenin as an active ingredient.

【0013】また、上記イミダゾールジペプチド類の塩
としては、塩酸、乳酸、酢酸、硫酸、クエン酸、アスコ
ルビン酸、リンゴ酸、コハク酸、アジピン酸、グルコン
酸、酒石酸等の塩が挙げられる。
Examples of the salts of the imidazole dipeptides include salts of hydrochloric acid, lactic acid, acetic acid, sulfuric acid, citric acid, ascorbic acid, malic acid, succinic acid, adipic acid, gluconic acid, tartaric acid and the like.

【0014】上記イミダゾールジペプチド類は、魚肉、
鶏肉、畜肉等に含まれており、それらから水抽出、熱水
抽出、アルコール抽出、超臨界抽出等の方法により抽出
したエキスを精製することにより得ることができる。
The above imidazole dipeptides include fish meat,
It is contained in chicken, animal meat, etc., and can be obtained by purifying an extract extracted therefrom by a method such as water extraction, hot water extraction, alcohol extraction, supercritical extraction and the like.

【0015】例えば、アンセリンは以下のようにして得
ることができる。まず、常法に従ってカツオ、マグロ、
ウシ、ニワトリ等の肉からエキスを調製し、適宜水を加
えて該エキスのブリックス(Bx.)を1〜10%に調
整した後、限外濾過膜(分画分子量5,000〜50,
000)を用いて高分子タンパク質を除去し、低分子ペ
プチド画分を回収する。次いで、文献(Suyama et al:
Bull. Japan. Soc. Scient. Fish., 33, 141-146, 196
7)の方法に従って、適宜濃縮した低分子ペプチド画分
を強酸性樹脂を用いたイオン交換クロマトグラフィーに
供し、溶出液を回収する。そして、この溶出液を脱塩し
た後pH調整し、凍結乾燥等により乾燥して得ることが
できる。
For example, anserine can be obtained as follows. First, skipjack, tuna,
An extract is prepared from meat such as cows and chickens, and water is appropriately added to adjust the Brix (Bx.) Of the extract to 1 to 10%. Then, an ultrafiltration membrane (fraction molecular weight 5,000 to 50,
000) to remove the high molecular weight protein and collect the low molecular weight peptide fraction. Then, the literature (Suyama et al:
Bull. Japan. Soc. Scient. Fish., 33, 141-146, 196
According to the method of 7), the appropriately concentrated low molecular peptide fraction is subjected to ion exchange chromatography using a strongly acidic resin, and an eluate is collected. Then, the eluate can be obtained by desalting, adjusting the pH, and drying by freeze-drying or the like.

【0016】また、カルノシンはブタ肉を原料として、
バレニンは鯨肉(例えばヒゲクジラ類)を原料として、
上記と同様の方法により得ることができる。
Carnosine is made from pork meat.
Valenin is made from whale meat (eg baleen whales)
It can be obtained by a method similar to the above.

【0017】本発明の抗疲労組成物は、上記イミダゾー
ルジペプチド類及び/又はその塩を10〜100質量%
含むことが好ましく、50〜100質量%含むことがよ
り好ましい。
The anti-fatigue composition of the present invention comprises the imidazole dipeptide and / or a salt thereof in an amount of 10 to 100% by mass.
It is preferably contained, more preferably 50 to 100% by mass.

【0018】また、上記基本的成分の他に、賦形剤、ミ
ネラル類、ビタミン類、糖類、香料等を適宜含むことが
できる。
Further, in addition to the above basic components, excipients, minerals, vitamins, sugars, fragrances and the like can be appropriately contained.

【0019】本発明の抗疲労組成物の製品形態は、錠
剤、粉末、顆粒、溶液、カプセル剤等が挙げられるが、
特に制限されない。
The product form of the anti-fatigue composition of the present invention includes tablets, powders, granules, solutions, capsules and the like.
There is no particular limitation.

【0020】本発明の抗疲労組成物の1日当りの有効摂
取量は、イミダゾールジペプチド類換算で1〜200m
g/体重kg、より好ましくは5〜30mg/体重kg
である。
The effective daily intake of the anti-fatigue composition of the present invention is 1 to 200 m in terms of imidazole dipeptides.
g / kg of body weight, more preferably 5-30 mg / kg of body weight
It is.

【0021】また、本発明の抗疲労組成物を、清涼飲
料、錠菓、スナック、粉末スープ、ソーセージ等の飲食
品に添加してもよい。その場合、一食当りの添加量はイ
ミダゾールジペプチド類換算で100〜2,000mg
が好ましく、400〜2,000mgがより好ましい。
イミダゾールジペプチド類の添加量が100mg未満で
あると抗疲労効果があまり期待できず、2,000mg
超であると飲食品の味に影響がでるため好ましくない。
Further, the anti-fatigue composition of the present invention may be added to foods and drinks such as soft drinks, tablet confections, snacks, powdered soups, sausages and the like. In that case, the addition amount per serving is 100 to 2,000 mg in terms of imidazole dipeptides.
Is preferable, and 400 to 2,000 mg is more preferable.
If the amount of imidazole dipeptides is less than 100 mg, the anti-fatigue effect cannot be expected so much, and 2,000 mg
If the amount is too large, the taste of food and drink is affected, which is not preferable.

【0022】[0022]

【実施例】以下、実施例を挙げて本発明を具体的に説明
する。 実施例1(アンセリンの調製) 常法に従って調製したカツオエキス(Bx.=55%)
10kgに、4倍量の水を加えて希釈した後、限外濾過
膜(分画分子量10,000)を用いて高分子タンパク
質を除去し、低分子ペプチド画分を回収した。この画分
を濃縮して、0.38Nクエン酸ナトリウム水溶液(p
H4.0)で平衡化した強酸性樹脂(商品名「Amberlit
e IR-120」、ロームアンドハース社製)を充填したカラ
ムクロマトグラフィーに供し、樹脂容量の4.5〜6.
0倍の0.38Nクエン酸ナトリウム水溶液(pH4.
0)で溶出して溶出画分を回収した。そして、この溶液
を脱塩し、pH調整した後、凍結乾燥して、粉末45g
を得た。得られた粉末を日立製アミノ酸分析計で分析し
たところ、アンセリン塩酸塩として98%の純度であっ
た。
The present invention will be specifically described below with reference to examples. Example 1 (Preparation of anserine) Skipjack extract (Bx. = 55%) prepared according to a conventional method
After diluting 10 kg with 4 volumes of water, the high molecular weight protein was removed using an ultrafiltration membrane (fraction molecular weight 10,000), and the low molecular weight peptide fraction was recovered. This fraction was concentrated and a 0.38N aqueous sodium citrate solution (p
H4.0) equilibrated with strong acidic resin (trade name “Amberlit
e IR-120 ", manufactured by Rohm and Haas Co., Ltd.).
0-fold 0.38N aqueous sodium citrate solution (pH 4.
The eluted fraction was eluted in 0) and collected. Then, the solution was desalted, adjusted to pH, and freeze-dried to obtain 45 g of powder.
I got When the obtained powder was analyzed by an amino acid analyzer manufactured by Hitachi, the purity was 98% as anserine hydrochloride.

【0023】実施例2(カルノシンの調製) 常法に従ってブタ肉から調製したエキス(Bx.=30
%)10kgを用いた以外は、実施例1と同様の方法
で、粉末24gを得た。この粉末はカルノシン塩酸塩と
して92%の純度であった。
Example 2 (Preparation of Carnosine) An extract (Bx. = 30) prepared from pig meat according to a conventional method
%) 24 g of powder was obtained in the same manner as in Example 1 except that 10 kg was used. This powder was 92% pure as carnosine hydrochloride.

【0024】実施例3(バレニンの調製) 常法に従ってヒゲクジラの肉から調製したエキス(B
x.=50%)10kgを用いた以外は、実施例1と同
様の方法で、粉末40gを得た。この粉末はバレニン塩
酸塩として92%の純度であった。
Example 3 (Preparation of Valenin) An extract (B) prepared from beef whale meat according to a conventional method
x. = 50%) Except that 10 kg was used, 40 g of powder was obtained in the same manner as in Example 1. This powder was 92% pure as varenin hydrochloride.

【0025】試験例(マウスを用いた強制運動負荷試
験) 6週齢のSPFマウス(雄)20匹を2群(各群10
匹)に分け、4時間絶食させた後、対照群には注射用水
を200mg/kg体重、試験群には実施例1で調製し
たアンセリン塩酸塩の水溶液(40mg/ml)をアン
セリン塩酸塩換算で200mg/kg体重となるよう
に、それぞれ強制的に経口投与した。
Test Example (Forced Exercise Test Using Mice) Two groups of 20 6-week-old SPF mice (male) (10
After a 4 hour fast, the control group was given 200 mg / kg body weight of water for injection, and the test group was given the aqueous solution of anserine hydrochloride (40 mg / ml) prepared in Example 1 in terms of anserine hydrochloride. Each of them was orally administered orally to 200 mg / kg body weight.

【0026】経口投与してから正確に1時間後に以下の
強制運動をマウスに負荷した。水温20℃の水を満たし
て空気を送り込み水面を波立たせた水槽(W265×D
427×H204mm)に、マウスを入れて遊泳時間の
測定を行なった。なお、マウスには、マウスの平均体重
の10%に相当する重りを負荷し、遊泳開始からマウス
が頭部を水面下に7秒以上沈めるまでの時間を遊泳時間
とした。
Exactly one hour after the oral administration, the following forced exercise was applied to the mice. A water tank filled with water at a water temperature of 20 ° C. and air was blown in to make the water surface rippling (W265 × D
427 × H204 mm) and the swimming time was measured with the mouse. The mouse was loaded with a weight equivalent to 10% of the average weight of the mouse, and the time from the start of swimming until the mouse sank its head under the water surface for 7 seconds or more was defined as the swimming time.

【0027】そして、上記遊泳時間の測定終了後3分間
経過した時点(1回目)及び30分間経過した時点(2
回目)で、マウスを針金に懸垂させて、落下するまでの
時間を測定した。
Then, at the time when 3 minutes have passed after the measurement of the swimming time (the first time) and at the time when 30 minutes have passed (2
In the second round), the mouse was hung on a wire, and the time until the mouse fell was measured.

【0028】さらに、上記運動負荷後、1時間経過して
から採血して血漿を分離し、血漿中の乳酸量を測定し
た。乳酸量の測定は、市販のキット(商品名:F−キッ
ト L−乳酸、ベーリンガーマンハイム株式会社製)を
用いて行なった。なお、上記の各測定結果は平均値±標
準誤差で表し、有意差の検定は、Studen't t−testに
より行なった。
Further, one hour after the exercise load, blood was collected to separate the plasma, and the amount of lactic acid in the plasma was measured. The amount of lactic acid was measured using a commercially available kit (trade name: F-kit L-lactic acid, manufactured by Boehringer Mannheim). In addition, each of the above measurement results was represented by an average value ± standard error, and a test for a significant difference was performed by Student't t-test.

【0029】図1には、遊泳時間の結果が示されてい
る。図1から、試験群は、対照群に比べて遊泳時間が長
くなる傾向が認められた。
FIG. 1 shows the results of the swimming time. From FIG. 1, the test group tended to have a longer swimming time than the control group.

【0030】図2、3には、1回目及び2回目の懸垂時
間の結果が示されている。図2、3から、いずれの場合
も試験群は対照群に比べて懸垂持続時間が長くなる傾向
が認められた。特に2回目の懸垂においては、試験群は
対照群に対して危険率0.01以下で有意に懸垂時間が
長くなる効果が認められた。
FIGS. 2 and 3 show the results of the first and second suspension times. 2 and 3, in each case, the test group tended to have a longer suspension duration than the control group. In particular, in the second suspension, the test group was found to have an effect of significantly increasing the suspension time at a risk factor of 0.01 or less relative to the control group.

【0031】図4には、運動負荷後1時間経過した時の
血漿乳酸量が示されている。図4から、試験群は対照群
に比べて危険率0.05%以下で有意に血漿中の乳酸量
が低いレベルに抑えられていることが分かる。
FIG. 4 shows the amount of plasma lactate one hour after the exercise load. From FIG. 4, it can be seen that the test group had significantly lower plasma lactic acid levels at a risk rate of 0.05% or less than the control group.

【0032】以上の結果から、アンセリンを経口摂取す
ることにより、運動能力が向上することが示唆された。
また、運動後の血漿中の乳酸量が低く抑えられているこ
とから、運動による筋肉の疲労を抑制していることが示
唆された。
The above results suggest that oral intake of anserine improves exercise performance.
In addition, since the amount of lactic acid in the plasma after exercise was kept low, it was suggested that muscle fatigue due to exercise was suppressed.

【0033】[0033]

【発明の効果】以上説明したように、本発明によれば、
イミダゾールジペプチド類及び/又はその塩を有効成分
として含有させることにより、運動能力の向上及び抗疲
労効果を有する抗疲労組成物を提供できる。
As described above, according to the present invention,
By containing imidazole dipeptides and / or salts thereof as an active ingredient, an anti-fatigue composition having improved exercise performance and an anti-fatigue effect can be provided.

【図面の簡単な説明】[Brief description of the drawings]

【図1】 マウスの遊泳時間測定の結果を示す図であ
る。
FIG. 1 is a diagram showing the results of measuring the swimming time of mice.

【図2】 マウスの1回目の懸垂時間測定の結果を示す
図である。
FIG. 2 is a diagram showing a result of a first suspension time measurement of a mouse.

【図3】 マウスの2回目の懸垂時間測定の結果を示す
図である。
FIG. 3 is a diagram showing the results of a second suspension time measurement of mice.

【図4】 運動負荷後1時間経過した時点のマウスの血
漿中の乳酸量を示す図である。
FIG. 4 is a diagram showing the amount of lactic acid in plasma of a mouse at the time point when one hour has passed after exercise load.

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 イミダゾールジペプチド類及び/又はそ
の塩を有効成分として含有することを特徴とする抗疲労
組成物。
1. An anti-fatigue composition comprising an imidazole dipeptide and / or a salt thereof as an active ingredient.
【請求項2】 前記イミダゾールジペプチド類が、アン
セリン、カルノシン及びバレニンから選ばれた少なくと
も1種以上である請求項1に記載の抗疲労組成物。
2. The anti-fatigue composition according to claim 1, wherein the imidazole dipeptide is at least one selected from anserine, carnosine and varenin.
【請求項3】 前記イミダゾールジペプチド類及び/又
はその塩を10〜100質量%含有する請求項1又は2
に記載の抗疲労組成物。
3. The method according to claim 1, wherein the imidazole dipeptide and / or a salt thereof is contained in an amount of 10 to 100% by mass.
3. The anti-fatigue composition according to item 1.
JP2000368299A 2000-12-04 2000-12-04 Anti-fatigue Expired - Fee Related JP4873778B2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2000368299A JP4873778B2 (en) 2000-12-04 2000-12-04 Anti-fatigue
US09/933,438 US6855727B2 (en) 2000-12-04 2001-08-20 Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect
TW090120843A TWI221413B (en) 2000-12-04 2001-08-24 Antifatigue composition
AT01307418T ATE345798T1 (en) 2000-12-04 2001-08-31 ANTI-FATIGUE COMPOSITIONS CONTAINING ANSERINE AND D-RIBOSE
DE60124658T DE60124658T2 (en) 2000-12-04 2001-08-31 Fatigue compositions containing anserine and D-ribose
EP01307418A EP1210940B1 (en) 2000-12-04 2001-08-31 Antifatigue composition comprising anserine and D-ribose
KR1020010053099A KR100805163B1 (en) 2000-12-04 2001-08-31 Antifatigue composition
CN01141170A CN1356103A (en) 2000-12-04 2001-10-08 Anti-Fatigue Composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000368299A JP4873778B2 (en) 2000-12-04 2000-12-04 Anti-fatigue

Publications (2)

Publication Number Publication Date
JP2002173442A true JP2002173442A (en) 2002-06-21
JP4873778B2 JP4873778B2 (en) 2012-02-08

Family

ID=18838577

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000368299A Expired - Fee Related JP4873778B2 (en) 2000-12-04 2000-12-04 Anti-fatigue

Country Status (1)

Country Link
JP (1) JP4873778B2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087022A1 (en) * 2004-03-12 2005-09-22 Ajinomoto Co., Inc. Food composition having antistress effect
WO2007029834A1 (en) * 2005-09-09 2007-03-15 Ajinomoto Co., Inc. Food composition
JP2007181421A (en) * 2006-01-06 2007-07-19 Yaizu Suisankagaku Industry Co Ltd Fish and shellfish extract highly containing imidazole dipeptide, food and drink containing imidazole dipeptide, and method for producing the fish and shellfish extract highly containing imidazole dipeptide
JP2008127355A (en) * 2006-11-22 2008-06-05 Yaizu Suisankagaku Industry Co Ltd Composition for relieving alcoholic drunkenness, and food and drink containing the same
WO2016031581A1 (en) * 2014-08-27 2016-03-03 株式会社ウイルス医科学研究所 Factor involved in fatigue and use of same
JPWO2015053337A1 (en) * 2013-10-09 2017-03-09 味の素株式会社 Food containing histidine and use thereof
JP6263820B1 (en) * 2017-09-01 2018-01-24 株式会社東洋新薬 Eating and drinking composition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6261559A (en) * 1985-09-12 1987-03-18 Asahi Chem Ind Co Ltd Concentrated nutrient composition
WO1998006278A1 (en) * 1996-08-12 1998-02-19 Harris, Roger Methods and compositions for increasing the anaerobic working capacity in tissues
JP2001046021A (en) * 1999-08-10 2001-02-20 Itoham Foods Inc Material for physical strength enhancement/recovery from fatigue, and food using the same
JP2002051730A (en) * 2000-08-08 2002-02-19 Nippon Meat Packers Inc Sporting food

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6261559A (en) * 1985-09-12 1987-03-18 Asahi Chem Ind Co Ltd Concentrated nutrient composition
WO1998006278A1 (en) * 1996-08-12 1998-02-19 Harris, Roger Methods and compositions for increasing the anaerobic working capacity in tissues
JP2001046021A (en) * 1999-08-10 2001-02-20 Itoham Foods Inc Material for physical strength enhancement/recovery from fatigue, and food using the same
JP2002051730A (en) * 2000-08-08 2002-02-19 Nippon Meat Packers Inc Sporting food

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005087022A1 (en) * 2004-03-12 2008-01-24 味の素株式会社 Food composition having anti-stress effect
WO2005087022A1 (en) * 2004-03-12 2005-09-22 Ajinomoto Co., Inc. Food composition having antistress effect
WO2007029834A1 (en) * 2005-09-09 2007-03-15 Ajinomoto Co., Inc. Food composition
JP2007181421A (en) * 2006-01-06 2007-07-19 Yaizu Suisankagaku Industry Co Ltd Fish and shellfish extract highly containing imidazole dipeptide, food and drink containing imidazole dipeptide, and method for producing the fish and shellfish extract highly containing imidazole dipeptide
JP4612549B2 (en) * 2006-01-06 2011-01-12 焼津水産化学工業株式会社 Imidazole dipeptides-rich seafood extract, imidazole dipeptides-containing food and drink, and method for producing imidazole dipeptides-rich seafood extract
JP2008127355A (en) * 2006-11-22 2008-06-05 Yaizu Suisankagaku Industry Co Ltd Composition for relieving alcoholic drunkenness, and food and drink containing the same
JPWO2015053337A1 (en) * 2013-10-09 2017-03-09 味の素株式会社 Food containing histidine and use thereof
WO2016031581A1 (en) * 2014-08-27 2016-03-03 株式会社ウイルス医科学研究所 Factor involved in fatigue and use of same
JPWO2016031581A1 (en) * 2014-08-27 2017-06-08 株式会社ウイルス医科学研究所 Factors involved in fatigue and their use
JP2020058355A (en) * 2014-08-27 2020-04-16 株式会社ウイルス医科学研究所 Factors related to fatigue, and their use
JP7033113B2 (en) 2014-08-27 2022-03-09 株式会社ウイルス医科学研究所 Factors involved in fatigue and their utilization
JP6263820B1 (en) * 2017-09-01 2018-01-24 株式会社東洋新薬 Eating and drinking composition
JP2019041687A (en) * 2017-09-01 2019-03-22 株式会社東洋新薬 Composition for eating and drinking

Also Published As

Publication number Publication date
JP4873778B2 (en) 2012-02-08

Similar Documents

Publication Publication Date Title
US6855727B2 (en) Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect
JP6255079B2 (en) Rapid-acting oral arginine level oral preparation containing citrulline and arginine
JP2022064912A (en) Method and composition for increasing muscle protein synthesis and/or functional strength in mammals as well as method of producing composition
EP3115047B1 (en) Debility preventative
JP2003274896A (en) Bitter taste reduction agent for amino acids tasting bitter and use thereof
JP2002065212A (en) Food composition for strengthening muscle, and muscle- strengthening agent
JP4484058B2 (en) Fatigue recovery food composition
JP2002338473A (en) Anti-fatigue composition
JP4873778B2 (en) Anti-fatigue
US20040043442A1 (en) Use of betaine in functional products having blood pressure lowering effects
CA2667667C (en) Solid or aqueous alkaline preparation comprising a creatine component, process for the production thereof and the use thereof
JPWO2003011056A1 (en) Food composition for recovery from fatigue
WO1998035664A1 (en) Athletic endurance increasing agent in food
JPS6354320A (en) Anti-alcoholic disease composition
JP6025538B2 (en) Branched-chain amino acid degradation odor inhibitor and degradation odor control method
JP4111428B2 (en) Osteoporosis preventive or therapeutic agent
JP2010006764A (en) Protein assimilation promoter
JP7008452B2 (en) Highly absorbable oral tyrosine preparation
JP4111429B2 (en) Osteoporosis preventive or therapeutic agent
WO2018079573A1 (en) Composition for improving decreased absorption in digestive tract, and composition for promoting absorption in digestive tract
JPH11279081A (en) Composition containing bitter material
JP2008255087A (en) Locomotor activity promotor
JP2017012191A (en) Degradation odor inhibitor of branched chain amino acid and degradation odor inhibition method

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101214

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110214

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110628

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110928

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111025

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111115

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111122

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141202

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4873778

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111025

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees